Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity
- PMID: 380801
Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity
Abstract
A review of the clinical data on azaserine, DON, and azotomycin reveals that these agents have limited but definite antitumor activity. All three drugs are analogs of L-glutamine and contain a diazo group. They have been studied as single agents in a wide variety of human malignancies and have also been included in trials using combination chemotherapy. Most of these studies were performed early in the history of clinical trials and, therefore, the method of reporting results and the evaluation criteria were quite different from those in use today. A renewed interest in these agents has been triggered by the remarkable activity of DON and azotomycin against human tumor lines implanted into nude mice. On the basis of this activity and the clinical data we have compiled, we feel that new clinical trials with these agents are warranted.
Similar articles
-
Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.Cancer Res. 1979 Aug;39(8):3220-4. Cancer Res. 1979. PMID: 572261
-
Antitumor effects of azaserine and DON.Cancer Treat Rep. 1979 Jun;63(6):1031-2. Cancer Treat Rep. 1979. PMID: 466642 No abstract available.
-
Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice.Cancer Treat Rep. 1982 Jan;66(1):179-81. Cancer Treat Rep. 1982. PMID: 6796268
-
Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (review).In Vivo. 1987 Jan-Feb;1(1):1-13. In Vivo. 1987. PMID: 2979758 Review.
-
Glutamine antagonists in chemotherapy.Adv Pharmacol Chemother. 1970;8:57-120. doi: 10.1016/s1054-3589(08)60594-3. Adv Pharmacol Chemother. 1970. PMID: 4400179 Review. No abstract available.
Cited by
-
Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways.Curr Neuropharmacol. 2017;15(4):620-636. doi: 10.2174/1570159X14666160509123042. Curr Neuropharmacol. 2017. PMID: 27157265 Free PMC article.
-
The Cremeomycin Biosynthetic Gene Cluster Encodes a Pathway for Diazo Formation.Chembiochem. 2015 Oct 12;16(15):2172-5. doi: 10.1002/cbic.201500407. Epub 2015 Sep 14. Chembiochem. 2015. PMID: 26278892 Free PMC article.
-
Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas.Invest New Drugs. 1990 Feb;8(1):113-9. doi: 10.1007/BF00216936. Invest New Drugs. 1990. PMID: 2188926 Clinical Trial.
-
The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor.Mol Cancer Ther. 2020 Feb;19(2):397-408. doi: 10.1158/1535-7163.MCT-19-0319. Epub 2019 Oct 8. Mol Cancer Ther. 2020. PMID: 31594823 Free PMC article.
-
Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.Biomed Res Int. 2015;2015:690492. doi: 10.1155/2015/690492. Epub 2015 Sep 6. Biomed Res Int. 2015. PMID: 26425550 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources